This study tests if a drug called **Tocilizumab**, combined with usual medicines, helps people with schizophrenia, a brain disorder that affects thinking and emotions. Tocilizumab is already used to treat arthritis and works by blocking a protein called **IL-6** which can cause inflammation (swelling and irritation) in the body. The study lasts **12 weeks** and involves 20 patients who will receive either Tocilizumab or a placebo (a substance with no treatment effect) every 4 weeks. Patients will visit the clinic **6 times** over the study period to receive their infusions and for tests to check their thinking skills and any side effects.

• The study involves 6 clinic visits over 12 weeks, with 3 infusions of the study drug.
• Participants must be adults (18-55 years) with stable schizophrenia, already on certain medications.
• Known side effects include headaches, high blood pressure, and possible infections.

Participants will be closely monitored and must not have recent infections or certain health conditions. The study is designed to see if reducing inflammation improves thinking skills in people with schizophrenia.